Overview

SM-1 vs. an Active Comparator in A Model of Transient Insomnia

Status:
Not yet recruiting
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effectiveness, safety and tolerability of a combination drug product (SM-1) containing diphenhydramine, zolpidem and lorazepam, in adult participants who sometimes have difficulty in falling asleep or staying asleep, but who do not have chronic insomnia. Participants will receive SM-1 or a combination of diphenhydramine and lorazepam during 2 one-night stays at a sleep center.
Phase:
Phase 2
Details
Lead Sponsor:
Sequential Medicine Ltd